Clinical Trials
16 trialsNCT02393625 2026-04-02
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Novartis
Phase 1 Active not recruiting
NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT01828112 2025-02-07
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
Phase 3 Completed
NCT01828099 2025-01-16
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
Phase 3 Completed
NCT03546894 2024-07-15
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Takeda
Completed
NCT02299505 2022-02-09
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 1 Completed
NCT02450903 2021-03-30
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Phase 2 Completed
NCT01772797 2020-12-19
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
Novartis
Phase 1 Completed
NCT02292550 2020-12-17
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Novartis
Phase 1 Completed
NCT01947608 2020-11-03
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Novartis
No longer available
NCT02336451 2020-04-21
Ascend-7
Novartis
Phase 2 Completed
NCT01685138 2019-03-26
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT01283516 2019-03-15
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Novartis
Phase 1 Completed
NCT02040870 2019-02-20
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Novartis
Phase 1/2 Completed
NCT01685060 2017-06-19
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Novartis
Phase 2 Completed